WESTMINSTER, Colo., Nov. 1 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (Nasdaq: ALTH), today announced that it will report its
2006 third quarter financial results on Friday, November 3, 2006, before
the open of the U.S. financial markets.
Paul L. Berns, President and Chief Executive Officer, and other members
of Allos' senior management will provide a company update and summary of
third quarter results via webcast and conference call on Friday, November
3, 2006 at 11:00 AM ET. The dial in number for U.S. residents to
participate is 877-407-8031. International callers should dial
201-689-8031. Participants should reference the Allos Therapeutics
conference call. An audio replay of the conference call will be available
from 5 PM ET on Friday, November 3, 2006, until 11:59 PM ET on Friday,
November 10, 2006. To access the replay, please dial 877-660-6853
(domestic) or 201-612-7415 (international); Replay pass codes (both
required for playback): account # 286; conference ID # 218565. The webcast
of this call will be available from the homepage and the investors/media
section of the Company's web site, http://www.allos.com and will be archived for
30 days.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused
on the development and commercialization of small molecule therapeutics for
the treatment of cancer. The Company has two product candidates in
late-stage clinical development: EFAPROXYN(TM) (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in women
with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also evaluating RH1,
a targeted chemotherapeutic agent, in a Phase 1 trial in patients with
advanced solid tumors. For additional information, please visit the
Company's website at http://www.allos.com.
Safe Harbor Statement
The 2006 third quarter results press release and conference call will
contain forward-looking statements that involve significant risks and
uncertainties, including those that can be found in the "Risk Factors"
section of Allos' Form 10-K for the year ended December 31, 2005 and in
Allos' periodic reports on Form 10-Q and Form 8-K. Allos is providing the
information contained in the press release and conference call as of the
date of the release and does not undertake any obligation to update any
forward- looking statements as a result of new information, future events
or otherwise. The Company cautions investors not to place undue reliance on
the forward- looking statements contained in the press release or the
conference call. No forward-looking statement can be guaranteed and actual
events and results may differ materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com/
CONTACT:
Jennifer Neiman, Corporate Communications of
Allos Therapeutics, Inc., +1-720-540-5227, jneiman@allos.com
|
